Cardio Vascular Dynamics (CVD) to develop Facilitated Force Angioplasty:
This article was originally published in Clinica
Executive Summary
Endosonics subsidiary Cardio Vascular Dynamics (US) has licensed the exclusive, worldwide rights to Facilitated Force Angioplasty (FFA) technology which uses a novel catheter design for controlled incision of atherosclerotic plaque. The technology mechanically controls the scoring and cutting of artherosclerotic plaque so that conventional angioplasty can be carried out. The California-based company has agreed to finalise the development of FFA, complete clinical trials and obtain worldwide marketing approvals. FFA was developed by Dr Michael Stillabower, a practising interventional cardiologist at the Medical Center of Delaware, California.
You may also be interested in...
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.